샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514119

세계의 바이오마커 시장

Biomarkers
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 413 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

바이오마커 시장은 2030년까지 2,352억 달러에 달할 전망입니다.

2023년에 963억 달러로 평가된 바이오마커 시장은 예측 기간 동안 복합 연간 성장률(CAGR) 13.6%로 성장하여 2030년에는 2,352억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 안전 바이오마커는 복합 연간 성장률(CAGR) 13.8%로 성장을 지속하고, 분석 기간 종료 시 898억 달러에 도달할 것으로 예측됩니다. 효능 바이오마커 분야의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 12.0%로 추정됩니다.

미국 시장은 249억 달러를 나타낼 전망이며 중국은 복합 연간 성장률(CAGR) 17.7%로 성장할 것으로 예측됩니다.

미국 바이오마커 시장은 2023년 249억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 578억 달러 규모에 이를 것으로 예측되며, 예측 기간 동안 복합 연간 성장률(CAGR) 17.7%입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 9.4%와 11.4%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 10.4%로 성장할 것으로 예측됩니다.

바이오마커 - 주요 동향과 촉진요인 요약

바이오마커는 질병의 식별과 관리를 위한 정확한 도구를 제공하고, 치료 효과를 높이고, 신약의 개발을 촉진함으로써 건강 관리에 혁명을 가져왔습니다. 이러한 생물학적 지표는 다양한 생물학적 상태와 상태를 나타내는 측정 가능한 신호이며, 질병 진단 및 치료 효과 모니터링에 매우 중요합니다. 처음에는 질병의 검출은 관찰 가능한 신체 증상과 시료 분석에 크게 의존했습니다. 그러나 수년간 기술의 현저한 진보로 수많은 바이오마커가 발견,개발되어 의료진단과 치료 옵션이 대폭 충실해졌습니다. 이러한 진화는 보다 빠르고 정확한 진단, 치료 전략 개선, 에러 최소화를 촉진하여 보다 좋고 비용 효율적인 의료 솔루션으로 이어집니다.

현대의료에서 바이오마커의 통합은 병태의 진단부터 치료 결과의 예측까지 다양한 기능에 이르고 있습니다. 이들은 분자, 방사선학, 조직학적, 생리학적 바이오마커와 같은 범주로 분류되며, 각각 독특한 역할을 합니다. 예를 들어, 분자 바이오마커는 혈액과 뇌척수액과 같은 생물학적 샘플에서 발견되며 분자의 상호작용과 생화학적 변화를 나타냅니다. 방사선학적 바이오마커는 영상검사로부터 얻어지고, 골밀도 등의 건강상태를 비침습적으로 평가합니다. 조직학적 바이오마커는 조직과 세포의 생화학적 변화를 반영하며 암 진단 및 병기 분류에 중요합니다. 생리적 바이오마커는 혈압과 심박수와 같은 신체 기능을 직접 알 수 있습니다. 이러한 바이오마커는 진단, 예후, 예측, 모니터링 등 건강 관리의 다양한 단계를 통해 질병 관리를 강화하고 환자의 치료 및 치료 전략을 최적화합니다.

바이오마커 분야의 성장은 여러 요인에 의해 야기됩니다. 차세대 시퀀싱, 고처리량 스크리닝, 바이오인포매틱스와 같은 탐지 기술의 혁신은 바이오마커 분석의 정확성과 속도를 향상시키고 적시에 정확한 진단에 필수적입니다. 바이오마커를 인공지능(AI)이나 빅데이터 분석과 통합함으로써 고도의 데이터 분석이 가능해져 질병 패턴의 예측과 치료 성적이 향상됩니다. 제약 업계에서는 바이오마커가 의약품 개발 프로세스를 간소화하고 약물 치료를 개별화함으로써 임상시험에 소요되는 시간과 비용을 줄일 수 있습니다. 바이오마커를 활용한 첨단 진단 플랫폼은 종합적인 건강 평가를 제공하여 임상 현장에서의 실용성을 높입니다. 게다가, 건강 의식 증가와 예방 의학의 동향은 소비자가 개별화된 건강 관리 솔루션을 요구하고 있기 때문에 바이오마커의 채용에 영향을 미치고 있습니다. 헬스케어에 대한 의사결정에 대한 소비자 참여 증가와 이를 지원하는 규제 프레임워크은 바이오마커 기반 검사 및 치료의 사용을 더욱 촉진합니다. 바이오마커 검사에 대한 보험 적용이 확대됨에 따라 이러한 진보된 진단이 더욱 친숙해지고, 바이오마커가 일상적인 의료 행위에 통합되어 최신 의료 진단과 치료 전략이 진전됩니다.

조사 대상 기업 예(주목의 합계 282사)

  • Abbott Molecular, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Epigenomics AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • QIAGEN NV
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global Biomarkers Market to Reach US$235.2 Billion by 2030

The global market for Biomarkers estimated at US$96.3 Billion in the year 2023, is expected to reach US$235.2 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2023-2030. Safety Biomarkers, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$89.8 Billion by the end of the analysis period. Growth in the Efficacy Biomarkers segment is estimated at 12.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.9 Billion While China is Forecast to Grow at 17.7% CAGR

The Biomarkers market in the U.S. is estimated at US$24.9 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$57.8 Billion by the year 2030 trailing a CAGR of 17.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.4% and 11.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Biomarkers - Key Trends and Drivers Summarized

Biomarkers have revolutionized healthcare by providing precise tools for disease identification and management, enhancing treatment efficacy, and fostering the development of new drugs. These biological indicators are measurable signals of various biological states or conditions, crucial for diagnosing diseases and monitoring the effectiveness of treatments. Initially, disease detection relied heavily on observable physical symptoms and sample analysis. However, with significant technological advancements over the years, the discovery and development of numerous biomarkers have greatly enriched medical diagnostics and treatment options. This evolution has facilitated earlier and more precise diagnoses, improved treatment strategies, and minimized errors, leading to better and more cost-effective healthcare solutions.

The integration of biomarkers into modern medicine spans various functions, from diagnosing conditions to predicting treatment outcomes. They are classified into categories such as molecular, radiographic, histologic, and physiologic biomarkers, each serving unique roles. For example, molecular biomarkers are found in biological samples like blood and cerebrospinal fluid, indicating molecular interactions and biochemical changes. Radiographic biomarkers, derived from imaging studies, non-invasively assess health conditions, such as bone density. Histologic biomarkers reflect biochemical changes in tissues or cells, crucial for diagnosing and staging cancers. Physiologic biomarkers, like blood pressure or heart rate, provide direct insights into bodily functions. These biomarkers enhance disease management through various stages of healthcare, including diagnostic, prognostic, predictive, and monitoring biomarkers, thereby optimizing patient care and treatment strategies.

The growth of the biomarker field is driven by several factors. Innovations in detection technologies, such as next-generation sequencing, high-throughput screening, and bioinformatics, have enhanced the precision and speed of biomarker analysis, essential for timely and accurate diagnoses. The integration of biomarkers with artificial intelligence (AI) and big data analytics enables sophisticated data analysis, improving disease pattern prediction and treatment outcomes. In the pharmaceutical industry, biomarkers streamline drug development processes and personalize drug therapies, reducing clinical trial time and costs. Advanced diagnostic platforms that leverage biomarkers offer comprehensive health assessments, enhancing their practical utility in clinical settings. Additionally, rising health awareness and preventive medicine trends influence biomarker adoption, as consumers seek personalized healthcare solutions. Increased consumer participation in healthcare decisions and supportive regulatory frameworks further drive the use of biomarker-based tests and therapies. The expansion of insurance coverage for biomarker tests makes these advanced diagnostics more accessible, embedding biomarkers into routine medical practice and advancing modern medical diagnostics and therapeutic strategies.

Select Competitors (Total 282 Featured) -

  • Abbott Molecular, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Epigenomics AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • QIAGEN NV
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biomarkers - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth of Biomarker-Based Diagnostics and Companion Diagnostics
    • Advancements in Genomics and Proteomics Technologies
    • Rising Adoption of Biomarkers in Drug Development and Clinical Trials
    • Impact of COVID-19 Pandemic on Biomarker Research and Development
    • Government Regulations and Standards for Biomarker Validation and Approval
    • Expansion of Biomarker Applications in Oncology and Chronic Diseases
    • Development of Liquid Biopsy and Non-Invasive Biomarker Technologies
    • Consumer Preferences for Early Detection and Preventive Healthcare
    • Role of Biomarkers in Enhancing Clinical Decision-Making
    • Market Penetration of Digital Health and Biomarker Integration
    • Influence of Artificial Intelligence and Machine Learning on Biomarker Discovery
    • Growth of Biomarker-Based Research in Neurological Disorders
    • Challenges Related to Biomarker Validation and Clinical Utility
    • Emerging Markets and Growth Opportunities in Developing Regions
    • Future Trends and Innovations in Biomarker Technologies and Applications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Efficacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Efficacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Efficacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Validation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Validation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Immunological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Immunological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Immunological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Personalized Medicines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 40: World Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • JAPAN
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • CHINA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • EUROPE
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • FRANCE
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • GERMANY
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • INDIA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030
  • AFRICA
    • Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Biomarkers by Type - Safety, Efficacy and Validation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Biomarkers by Type - Safety, Efficacy and Validation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Biomarkers by Type - Percentage Breakdown of Value Sales for Safety, Efficacy and Validation for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Biomarkers by Application - Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Biomarkers by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics, Personalized Medicines and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Biomarkers by Disease - Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Biomarkers by Disease - Percentage Breakdown of Value Sales for Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases and Other Diseases for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제